Clinical trials: Adult-onset Diabetes
Diabetes Mellitus, Type 1 Diabetes, Diabetes Mellitus, Type 2
RIGHTEST iFree 2 CGM in Pregnant Women With Diabetes Study
This study will evaluate the accuracy and safety of the RIGHTEST iFree 2 Continuous Glucose Monitoring (CGM) System in pregnant women with type 1 diabetes, type 2 diabetes, or gestational diabetes.
- Conditions
- Diabetes Mellitus, Type 1 Diabetes, Diabetes Mellitus, Type 2, Diabetes, Gestational
- Trial name
- NCT07889388
- Testing
- RIGHTEST iFree 2 Continuous Glucose Monitoring System
- Where
- Germany
- Volunteers
- 104 people
- Sponsor
- Bionime Corporation
Diabetes Mellitus, Type 2
GW823093C For The Treatment Of Type 2 Diabetes Mellitus
This study was designed to find dose response and as extension in treatment of GW823093C.
- Trial name
- NCT00370942
- Testing
- GW823093C A, GW823093C B, GW823093C C
- Where
- 5 sites in Japan
- Volunteers
- 159 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus
Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes
The purpose of the study is to compare the pharmacodynamic effects of lixisenatide (AVE0010), in comparison to liraglutide, as an add-on treatment to metformin, over a period of 4 weeks of treatment.
- Trial name
- NCT01175473
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Liraglutide
- Where
- 7 sites in Germany
- Volunteers
- 148 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Safety and Efficacy Study of Dutogliptin in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin
The purpose of this study is to demonstrate the safety and tolerability of dutogliptin over 52 weeks.
- Trial name
- NCT00998686
- Testing
- dutogliptin, sitagliptin
- Where
- 44 sites in United States, Argentina and 4 more
- Volunteers
- 650 people
- Sponsor
- Phenomix
Type 2 Diabetes Mellitus (T2DM)
A Study to Compare the Efficacy and Safety of GZR102 Injection and GZR18 Injection in Type 2 Diabetes Mellitus
This is a multicenter, randomized, open-label, positive controlled efficacy exploration study. To compare the efficacy and safety of once-weekly GZR102 Injection and Bi-Weekly GZR18 Injection in Chinese adult subjects with type 2…
- Trial name
- NCT07055386
- Testing
- GZR102, GZR18
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Gan & Lee Pharmaceuticals.
Diabetes Mellitus, Type 2
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
This is a multi-center, open-label, parallel-group, randomized controlled study in subjects with type 2 diabetes using multiple daily injection (MDI) insulin therapy.
- Trial name
- NCT04090242
- Testing
- BD Diabetes Care Application (for mobile devices) PLUS use of BD Nano Pen Needle
- Where
- 4 sites in United States
- Volunteers
- 58 people
- Sponsor
- Becton, Dickinson and Company
Type 2 Diabetes
Human Bioequivalence Test of Liraglutide Injection
To evaluate the bioequivalence of The liraglutide injection produced by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Victoza® produced by Novo Nordisk (China) Pharmaceutical Co., Ltd for single dose in healthy subjects,so…
- Trial name
- NCT05029076
- Testing
- Liraglutide injection, Victoza
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Diabetes Mellitus, Type 2
A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (ie, blood levels of JNJ-28431754) and pharmacodynamics (ie, urine and blood levels of glucose) of JNJ-28431754 compared to placebo in patients…
- Trial name
- NCT00963768
- Testing
- JNJ 28431754
- Where
- 3 sites in United States, Germany and 1 more
- Volunteers
- 116 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Diabetes Mellitus, Type 2
Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes
Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. This is a 28-week extension to a study to assess the safety and effectiveness of vildagliptin, an unapproved drug, in…
- Trial name
- NCT00138515
- Testing
- vildagliptin
- Where
- United States
- Volunteers
- 418 people
- Sponsor
- Novartis
Diabetes Mellitus, Type 2
Study In People With Type 2 Diabetes
This Phase 2 dose-ranging study will evaluate the efficacy, safety and tolerability of a range of doses of GW677954 compared with placebo over sixteen weeks of treatment in subjects with T2DM (Type 2 Diabetes Mellitus).
- Trial name
- NCT00196989
- Testing
- Pioglitazone, GW677954
- Where
- 143 sites in United States, Argentina and 11 more
- Volunteers
- 448 people
- Sponsor
- GlaxoSmithKline
Acute Coronary Syndrome
Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)
Primary Objective: To demonstrate that lixisenatide can reduce cardiovascular (CV) morbidity and mortality (composite endpoint of CV death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable…
- Trial name
- ELIXA (NCT01147250)
- Testing
- Lixisenatide (AVE0010)
- Where
- 829 sites in United States, Argentina and 47 more
- Volunteers
- 6,068 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 2
Observational Safety Study in Subjects With Type 2 Diabetes Mellitus Starting or Switching to Biphasic Insulin Aspart 30 Treatment
This study is conducted in Europe. The aim of this study is to investigate safety and efficacy in subjects with type 2 diabetes mellitus starting or switching to biphasic insulin aspart 30 (NovoMix® 30) treatment.
- Trial name
- NCT01548235
- Testing
- biphasic insulin aspart 30
- Where
- Denmark
- Volunteers
- 423 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Comparison of Two Biphasic Insulin Aspart 30 Treatment Regimens in Subjects With Type 2 Diabetes Not Achieving HbA1c Treatment Targets on OADs Alone
This trial is conducted in Asia. The aim of this trial is to compare the glycaemic control when subjects initiate a biphasic insulin aspart 30 treatment followed by an intensified treatment if treatment target of HbA1c below 7%…
- Trial name
- NCT01215435
- Testing
- biphasic insulin aspart 30
- Where
- Iran
- Volunteers
- 245 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus
Efficacy and Safety Study of SYR-619 in Treating Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to determine the efficacy and safety of SYR-619, once daily (QD), in subjects with type 2 diabetes mellitus who have not achieved glycemic control with diet and exercise, or by taking metformin.
- Trial name
- NCT00763347
- Testing
- SYR-619, Alogliptin
- Volunteers
- 82 people
- Sponsor
- Takeda
Type 2 Diabetes, Obesity
Post Marketing Study in Subjects Who Have Type 2 Diabetes Using the EndoBarrier™ Gastrointestinal Liner
The purpose of this study is to evaluate EndoBarrier Gastrointestinal Liner in the post marketing environment in subjects who are obese and have Type 2 Diabetes.
- Trial name
- NCT01114438
- Testing
- EndoBarrier Gastrointestinal Liner
- Where
- 3 sites in United Kingdom
- Volunteers
- 45 people
- Sponsor
- Morphic Medical Inc.
Type 2 Diabetes
Mechanistic Study of ISIS ISIS-APOCIIIRX in Type 2 Diabetes
The purpose of this study is to evaluate the effects of ISIS ISIS-APOCIIIRX on Triglyceride Levels and Insulin Sensitivity in Subjects with Type 2 Diabetes on stable treatment with metformin.
- Trial name
- NCT01647308
- Testing
- ISIS-APOCIIIRX
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Growth Hormone Deficiency, Neoplasms
A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety Information and Clinical Parameters
The aim of this study is to look at the long-term safety and clinical parameters of somapacitan in paediatric participants with growth hormone deficiency under routine clinical practice conditions.
- Conditions
- Growth Hormone Deficiency, Neoplasms, Diabetes Mellitus Type 2
- Trial name
- NCT06709040
- Testing
- Somapacitan
- Where
- United Kingdom
- Volunteers
- 500 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 10773 at two different doses compared to placebo during long term treatment (78 weeks) in combination with basal insulin in patients…
- Trial name
- NCT01011868
- Testing
- BI 10773 low dose, BI 10773 high dose
- Where
- 99 sites in United States, Denmark and 5 more
- Volunteers
- 494 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes
The purpose of this study is to investigate the effect of bexagliflozin in lowering hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT02715258
- Testing
- Bexagliflozin
- Where
- 23 sites in United States, Canada
- Volunteers
- 210 people
- Sponsor
- Theracos
Type II Diabetes Mellitus
A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of Oral HMS5552 in Healthy Volunteers
The objectives of this study is to determine the safety profiles, tolerability, pharmacokinetics and pharmacodynamics of HMS5552 following single ascending doses in healthy adult subjects.
- Trial name
- NCT01952535
- Testing
- HMS5552
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Hua Medicine Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.